BIOMAT Database Logo BIOMAT Database Logo

Topical acyclovir treatment of herpes zoster in immunocompromised patients. 1985

M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti

Topical acyclovir favorably influences the healing of localized herpes zoster in immunocompromised patients. This therapy, or placebo, was applied to forty-three patients in a random access, double-blind trial, four times daily for 10 days, beginning within 72 hours after the onset of skin lesions. The mean time to pustulation is decreased from 12.4 to 6.7 days and the mean time to crusting is decreased from 16.0 to 11.4 days (p = 0.038 and 0.086, respectively) by topical treatment. The mean time to 50% healing is decreased from 24.5 to 15.2 days and the mean time to 100% healing is decreased from 34.9 to 25.8 days (p = 0.023 and 0.033, respectively). Favorable effects in treated patients are not associated with a more rapid decline in lesion virus titer, but do accrue without any toxicity.

UI MeSH Term Description Entries
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D008232 Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified. Duncan's Syndrome,X-Linked Lymphoproliferative Syndrome,Duncan Disease,Epstein-Barr Virus Infection, Familial Fatal,Epstein-Barr Virus-Induced Lymphoproliferative Disease In Males,Familial Fatal Epstein-Barr Infection,Immunodeficiency 5,Immunodeficiency, X-Linked Progressive Combined Variable,Lymphoproliferative Disease, X-Linked,Lymphoproliferative Syndrome, X-Linked, 1,Purtilo Syndrome,X-Linked Lymphoproliferative Disease,X-Linked Lymphoproliferative Disorder,Disease, Duncan,Disease, X-Linked Lymphoproliferative,Diseases, X-Linked Lymphoproliferative,Disorder, Lymphoproliferative,Disorder, X-Linked Lymphoproliferative,Disorders, Lymphoproliferative,Disorders, X-Linked Lymphoproliferative,Epstein Barr Virus Induced Lymphoproliferative Disease In Males,Epstein Barr Virus Infection, Familial Fatal,Familial Fatal Epstein Barr Infection,Immunodeficiency 5s,Immunodeficiency, X Linked Progressive Combined Variable,Lymphoproliferative Disease, X Linked,Lymphoproliferative Diseases, X-Linked,Lymphoproliferative Disorder,Lymphoproliferative Disorder, X-Linked,Lymphoproliferative Disorders, X-Linked,Lymphoproliferative Syndrome, X-Linked,Lymphoproliferative Syndromes, X-Linked,Purtilo Syndromes,Syndrome, Purtilo,Syndrome, X-Linked Lymphoproliferative,Syndromes, Purtilo,Syndromes, X-Linked Lymphoproliferative,X Linked Lymphoproliferative Disease,X Linked Lymphoproliferative Disorder,X Linked Lymphoproliferative Syndrome,X-Linked Lymphoproliferative Diseases,X-Linked Lymphoproliferative Disorders,X-Linked Lymphoproliferative Syndromes
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006562 Herpes Zoster An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed) Shingles,Zona,Zoster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Immunocompromised patients, herpes zoster and acyclovir.
May 1996, The New Zealand medical journal,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Acyclovir for immunocompromised patients with herpes zoster.
November 1983, The New England journal of medicine,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Acyclovir halts progression of herpes zoster in immunocompromised patients.
June 1983, The New England journal of medicine,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Treatment of disseminated herpes zoster in six severely immunocompromised patients: acyclovir and vidarabine.
January 1989, Japanese journal of medicine,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Topical acyclovir in herpes zoster ocular involvement.
August 1981, The British journal of ophthalmology,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Response of immunocompromised patients with acute herpes zoster to intravenous acyclovir.
June 1987, Minnesota medicine,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
[Herpes zoster--treatment with acyclovir].
January 1997, Medicinski pregled,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Herpes zoster in immunocompromised patients.
September 2007, Herpes : the journal of the IHMF,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Herpes zoster oticus: treatment with acyclovir.
February 1992, The Annals of otology, rhinology, and laryngology,
M J Levin, and J A Zaia, and B J Hershey, and L G Davis, and G V Robinson, and A C Segreti
Managing herpes zoster in immunocompromised patients.
September 2007, Herpes : the journal of the IHMF,
Copied contents to your clipboard!